Latest news with #DELTA
Business Wire
7 days ago
- Health
- Business Wire
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle in the treatment of adults with mild to severe Palmoplantar Pustulosis (PPP). PPP is the first disease for which LEO Pharma will investigate delgocitinib cream since completion of the Phase 3 DELTA trials in Chronic Hand Eczema (CHE). ' The DELTA NEXT trial in PPP represents an exciting new chapter in the clinical development journey of delgocitinib cream,' said Christophe Bourdon, Chief Executive Officer, LEO Pharma. 'PPP is a disease with few treatment options that can severely affect quality of life. We are hopeful that this therapy could potentially provide much-needed help for patients suffering from this devastating condition.' PPP is an uncommon, chronic, inflammatory, relapsing skin disease characterized by repeated episodes of sterile pustules alongside erythema, blistering and scaly skin on the palms and/or soles of the feet. 3,4 PPP is associated with a high patient burden, resulting in significant impairment of quality of life. Patients often experience pain, fatigue, and the condition can be triggered by factors such as smoking, infections, and stress. PPP is associated with comorbidities such as thyroid dysfunction and metabolic syndrome. 4 There are currently no approved advanced systemic treatments for PPP in the U.S. or Europe. 5 PPP is associated with complex T-cell activation patterns, which may be why many biologics that target individual T helper cell populations have shown limited efficacy in clinical trials. 6 Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor shown to inhibit the activity of all four JAKs, which are involved in inflammatory signaling. 1,2 Using delgocitinib cream's mechanism of action, the trial will investigate the potential benefit of inhibiting multiple JAKs to treat PPP. 'I've seen firsthand how PPP can severely disrupt patients' lives, making it painful to walk, perform activities of daily living and impacting their ability to work,' said Dr. Robert Bissonnette, international coordinating investigator (ICI) on the DELTA NEXT trial and Chairman at Innovaderm Montreal, Canada. 'Despite the significant burden it places on patients, treatment options remain limited. There is a real and urgent need for effective therapies." The DELTA NEXT trial plans to recruit up to 135 patients with active, chronic, mild to severe PPP for whom topical corticosteroids are inadequate or inadvisable. Participants will be recruited across 40-45 sites in the United States, Canada, the United Kingdom, Germany, and Poland. Currently, delgocitinib cream is approved for adults in the European Union, United Kingdom, Switzerland, and the United Arab Emirates for the treatment of moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate, and is under review in other markets, including the United States. For more information on the DELTA NEXT trial, go to Notes to editors About Delgocitinib Cream Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor. It prevents the activation of the JAK-STAT pathway by blocking the signaling of several inflammatory cytokines, thereby suppressing the inflammatory cascade and preventing the downregulation of important barrier genes. 7 Delgocitinib cream is currently approved in the European Union, the United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. It is under review in other markets, including the United States. In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib cream for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. About the DELTA NEXT Trial DELTA NEXT is a phase 2a, randomized, double-blind, two-arm, vehicle control, adaptive design proof-of-concept trial to assess the efficacy and safety of twice-daily delgocitinib cream compared with cream vehicle in adult subjects with mild to severe PPP. The DELTA NEXT trial plans to recruit up to 135 patients with active, chronic, mild to severe PPP for whom topical corticosteroids are inadequate or inadvisable. Participants will be randomized into a 2:1 ratio to receive either delgocitinib cream or cream vehicle. Participants will be recruited across 40-45 sites in the United States, Canada, the United Kingdom, Germany, and Poland. About Palmoplantar Pustulosis (PPP) Palmoplantar Pustulosis (PPP) is an uncommon chronic, inflammatory, relapsing skin disease characterized by repeated episodes of sterile pustules alongside erythema, blistering and scaly skin on the palms and/or soles of the feet. 3,4 The disease is more common in females, with the estimated prevalence ranging from 0.01% to 0.05%. 3,4 The mean age of patients ranges from 40 to 58 years and is often associated with smoking, thyroid-gland abnormalities, and nickel sensitivity. 4,8 PPP is associated with a significant clinical burden. Patients often experience pain, fatigue, and the condition can be associated with hyperlipidemia and high blood pressure. 8 The condition has been shown to have a greater impairment on work and daily life than plaque psoriasis. 8 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit References Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41-51. Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. Exp Dermatol. 2018;27(1):22-29. Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252. Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments. Am J Clin Dermatol. 2020;21(3):355-370. Xu JM, Wang HM, Jin HZ. An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations. Expert Rev Clin Immunol. 2023;19(5):499-516. McCluskey D, Benzian-Olsson N, Mahil SK, et al. Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol. 2022;150(4):882-893. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [published correction appears in Ther Clin Risk Manag. 2021 Mar 18;17:233.]. Ther Clin Risk Manag. 2020;16:1319-1332. Lebwohl MG, Medeiros RA, Strober B, et al. Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry. J Psoriasis Psoriatic Arthritis. 2023;8:56–65.
Malaysian Reserve
26-05-2025
- Automotive
- Malaysian Reserve
Charge Into The Cold: EcoFlow Launches EOFY Sale
SYDNEY, May 26, 2025 /PRNewswire/ — As Aussies prepare for winter getaways and school holidays road trips, EcoFlow is offering limited-time End of Financial Year (EOFY) savings on its popular DELTA series of portable power solutions and accessories. The EcoFlow DELTA series is designed to handle heavy-duty power needs – offering fast charging, large battery capacity and enough output to run appliances, power tools and entertainment gear. Whether you're braving the cold outdoors or need extra power for backyard entertaining, these winter-ready essentials deliver power when and where you need it most. With discounts of up to 33%, EcoFlow's EOFY sale includes high-capacity portable power stations and vehicle-ready alternator charging bundles, perfect for 4WDs, RVs and caravans. On sale from today (May 26) to June 30: EcoFlow DELTA 2 Max + 800W Alternator Charger – Now $2,599, originally $3,198 (19% off) EcoFlow DELTA Pro 3 – Now $4,599, originally $4,999 (8% off) EcoFlow 800W Alternator Charger – Now $549, originally $599 (8% off) On sale from June 12 to June 30: EcoFlow DELTA Pro – Now $2,999, originally $4,499 (33% off) EcoFlow DELTA 2 + 800W Alternator Charger – Now $1,599, originally $1,798 (11% off) EcoFlow DELTA 2 – Now $1,099, originally $1,199 (8% off) Choosing the right power this winter EcoFlow's DELTA series offers flexible power solutions to suit your winter needs. According to recent EcoFlow data, the average daily energy consumption varies significantly across models: EcoFlow DELTA Pro (120.9kWh) and EcoFlow DELTA Pro 3 (118.0kWh) are top performers, which makes them ideal for portable heaters, induction cooktops or multiple appliances during long road trips. EcoFlow DELTA 2 (37.8kWh) and EcoFlow DELTA 2 Max (35.7kWh) are perfect for charging smaller devices, running lights or powering small fridges on weekend getaways. The EcoFlow EOFY sale runs until June 30, 2025, while stock lasts. To learn more or shop the full range, visit here. New Product Launch: EcoFlow 500W alternator charger now available Following the success of its 800W Alternator Charger, EcoFlow has expanded its vehicle charging lineup with the launch of a new 500W version – just in time for winter road trips. The EcoFlow 500W Alternator Charger offers a more compact and cost-effective option for users with smaller power needs, making it an ideal match for the EcoFlow RIVER series and the EcoFlow DELTA 2 when paired with the XT150 cable. Like its larger counterpart, the 500W model allows you to recharge your portable power station directly from your vehicle's alternator while charging, giving users more flexibility to stay powered on the go, without needing to stop and plug into a wall socket or rely on solar. About EcoFlowEcoFlow is a leading provider of eco-friendly energy solutions, committed to powering a new world. Since its founding in 2017, EcoFlow has aimed to be the FIRST in power solutions — Flexible, Innovative, Reliable, Simple, and Thorough — for individuals and families, whether at home, outdoors or on the go. With a smart manufacturing center in China, and headquarters in the USA, Germany and Japan, EcoFlow has empowered over 4.5 million users in 140 markets worldwide. For more information, visit Media ContactAllison Worldwide for EcoFlow Australiaecoflowanz@
Sassy Mama
20-05-2025
- General
- Sassy Mama
Is Your Child Ready For P1? Build Their Confidence With 1-On-1 Or Small Group English Lessons
Looking for a way to help your child learn to read before Primary 1? Discover how British Council's 1-on-1 and small group English lessons help students thrive at their upcoming Open House! Starting Primary 1 is a big milestone! Preparing your child for this crucial transition can be exciting if you have the right support. That's why British Council is here to support your child with personalised 1-on-1 and small group private English lessons for kids that will lay the essential foundation they need so they will be ready to speak, read and write confidently when they start Primary 1. Customised English lessons by experienced teachers British Council's 1-on-1 and small group private English lessons for kids equip them with the tools and practice they need to read fluently. Kids as young as Kindergarten 1 can join their English enrichment courses. Lessons are fully customised to meet your child's needs and delivered by highly experienced and qualified teachers who hold University of Cambridge CELTA or DELTA qualifications. Understanding that each child is different, the English teacher tailors each lesson to your child's pace with effective and trusted resources, including materials aligned with the syllabus set by the Singapore Ministry of Education (MOE). Pre-schoolers are engaged with active learning with lots of hands-on exploration to develop your child's speaking confidence and socialisation skills. Whether you want your child to study with one or two friends, have lessons at our centres or prefer the convenience of learning from home, British Council offers a variety of instruction methods to suit your busy schedule. When your child first begins, their teacher will assess their current level and provide feedback and insight into the course content, as well as a post-course consultation to track their progress. British Council also offers English lessons for teens and adults, because learning is a lifelong journey. Register for their upcoming Open House If your child is entering Primary 1 in January 2026, don't miss the British Council Young Learners Open House! Register for their Open House to get a glimpse of how they instil a love of the English language through their engaging, interactive lessons. Take a deep dive into their curriculum and teaching methods, and get all of your burning questions answered by their friendly Academic team. Enjoy an exclusive discount of $100 off when you register at the Open House for a 10-hour package for their 1:1 or small-group lessons for kids, teens or adults. British Council, 30 Napier Road, Singapore 258509 and 480 Lorong 6 Toa Payoh, #09-01 HDB Hub, East Wing, Singapore 310480 (or at a location of your choice!), Read more: Best English Tuition Centres In Singapore
Khaleej Times
27-04-2025
- Business
- Khaleej Times
AI expert captivates global leaders at Dubai AI Festival 2025
In an intellectually stimulating keynote address that drew global attention, Dr. Abdalla Kablan, award-winning AI expert, author, and serial entrepreneur, delivered a powerful session at the Dubai AI Festival 2025, redefining the future of technology through his groundbreaking concept: Artificial Wisdom. Held under the patronage of Sheikh Hamdan Bin Mohammed Bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister and Minister of Defence of the UAE, the Dubai AI Festival has emerged as one of the most prestigious global events exploring artificial intelligence's role in shaping tomorrow's digital economies. In his keynote titled 'Artificial Wisdom: The Future Beyond AI,' Dr. Kablan introduced a radical yet essential evolution in technological thinking, one that elevates machines from raw processing and data-driven decision-making to systems guided by ethics, empathy, and long-term value. 'Artificial Wisdom is the natural next step for humanity,' said Dr. Kablan during the session. 'It's where we stop asking what machines can do, and begin asking what they should do.' This philosophy infused with deep ethical awareness, human context, and societal responsibility resonated with an international audience of policymakers, technologists, investors, and innovators eager to reimagine how AI can be built not just to think, but to understand. A Global Technology Luminary With a career spanning entrepreneurship, academia, and government advisory, Dr. Abdalla Kablan has consistently stood at the intersection of technology and societal progress. Known for founding and exiting several high-impact tech ventures, he has also played a pivotal role in shaping national strategies on artificial intelligence and blockchain. A trusted voice in global innovation circles, Dr. Kablan is admired for his ability to translate complex ideas into visionary frameworks chief among them, Artificial Wisdom, a concept that continues to gain momentum among industry leaders, investors, and policymakers worldwide. The vision is already being implemented through his leadership at DELTA Wealth Partners, the AI-driven venture capital firm he founded and leads as CEO. With a unique mandate to invest in next-generation AI, deep-tech, and automation startups, DELTA Wealth Partners applies the principles of Artificial Wisdom to strategic, long-term investing. The firm's mission is to fund technologies that are not just powerful, but principled those that hold the potential to drive sustainable innovation and elevate society. Under Dr. Kablan's leadership, DELTA has become a force in the Middle East and globally, standing at the intersection of intelligent capital and conscious innovation.
Yahoo
14-02-2025
- Politics
- Yahoo
Ukraine's Defence Ministry dismisses Utiushev, head of key digital weapon development
The Ministry of Defence of Ukraine on 12 February issued an order dismissing Marat Utiushev from his position as head of the Centre for Innovation and Defence Technology Development. Source: Utiushev on Facebook on 13 February Details: The main development by Utiushev and the Centre is the DELTA system, which allows military personnel to view the battlefield in real time and plan operations. Utiushev said that DELTA has rapidly evolved in recent years, integrating NATO standards. The system has won first place in various NATO exercises and conferences. Quote: "DELTA became a key digital tool in the early months of the full-scale war brought on by the Russians. It was used to defend Kyiv, Kharkiv, Kherson and Zmiinyi (Snake) Island, during the sinking of the Moskva cruiser and in the destruction of Russian ships in the Black Sea. In 2024 alone, the number of users increased fourfold, and DELTA has become as widely known as Excel – everyone knows it, and many use it." He also mentioned that the Innovation Centre has been working on several successful projects, including the artificial intelligence platform Avengers for detecting military equipment and the UA DRONE ID protocol for integrating drones into combat systems, since 2022. Sources from Forbes Ukraine say that Defence Minister Umierov's decision may be connected to the appointment of Valerii Churkin as his deputy on 7 February. Churkin, in his new role, is responsible for overseeing the development of defence innovations. Quote from a source: "Perhaps their visions for DELTA's development don't align." However, Churkin has not expressed any open dissatisfaction with Utiushev. Background: Ukraine's Defence Forces automatically detect 12,000 items of Russian equipment every week using the artificial intelligence platform Avengers, developed by the Ministry of Defence's Innovation Centre. The AI platform enables operators to make faster and more effective decisions while also reducing the risk of errors caused by fatigue. This integration is already successfully implemented in the VEZHA streaming module of the DELTA combat system. Support UP or become our patron!
